DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Gregory Renza - 2 Renza - 2 Oprah Winfrey - 1 Eli Lilly - 1 they've - 1 Lilly's - 1 Lilly's Zepbound - 1 Andy Acker - 1
Top related locs:
Friday's Eccogene MedTech 3Q23 South San Francisco , California Bengaluru
Top related orgs:
Novo Nordisk - 1 Wall Street - 1 Wall - 1 RBC Capital - 1 Pfizer - 1 Structure Therapeutics - 1 AstraZeneca - 1 Leerink - 1

Search resuls for: "Gregory Renza"


4 mentions found


☆ Oprah's flip on weight loss drugs is a sign of what's to come for the 'Ozempic trade' in 2024
  + stars: | 2023-12-25 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +10 min
Lilly's Zepbound recently entered the weight loss market, and is off to a strong start. But what's ahead for the weight loss trade in 2024? Beyond weight loss One of 2023's most pivotal events in the space was Novo Nordisk's release of top line results from its Select trial in August . In 2023, the exuberance around weight loss drugs roiled markets in many unexpected ways. The affected companies have also been very vocal in addressing how they plan to coexist with these weight loss products.
Persons: Oprah Winfrey, Eli Lilly, they've, Lilly's, Lilly's Zepbound, Andy Acker, Janus Henderson's, Lilly, Novo, FactSet, Acker, Janus, Buzz, Gregory Renza, Renza, Goldman Sachs, Chris Shibutani, Mike Kratky, Kratky, Dexcom, Leerink, Winfrey, I've, Winfrey's, Michael Bloom Organizations: Novo Nordisk, Wall Street, Wall, RBC Capital, Pfizer, Structure Therapeutics, AstraZeneca, Leerink, Nestle, Oprah Daily, Winfrey, International Locations: Friday's, Eccogene, MedTech, 3Q23
☆ Amgen completes $27.8 bln Horizon Therapeutics deal
  + stars: | 2023-10-06 | by ( ) www.reuters.com   time to read: +1 min
An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013 photo. Amgen, which has gained Horizon's two key products Tepezza and Krystexxa, said it will provide an updated annual forecast during its third-quarter earnings call. RBC Capital Markets analyst Gregory Renza expects Amgen's updated forecast to weave in revenue from Horizon's drugs, which could partially offset the company's "maturing product line". Tepezza could be a "core driver" for Amgen, Renza said, adding that the drug can bring in $3.9 billion in peak sales. Reporting by Mariam Sunny and Sriparna Roy in Bengaluru; Editing by Anil D'Silva and Sherry Jacob-PhillipsOur Standards: The Thomson Reuters Trust Principles.
Persons: Robert Galbraith, Gregory Renza, Renza, Mariam Sunny, Sriparna Roy, Anil D'Silva, Sherry Jacob, Phillips Organizations: Horizon Therapeutics, U.S . Federal Trade Commission, FTC, RBC Capital Markets, Thomson Locations: South San Francisco , California, Bengaluru
☆ U.S. FDA approves Acadia's Rett syndrome drug
  + stars: | 2023-03-14 | by ( ) www.reuters.com   time to read: +3 min
The approval comes months after the FDA declined to approve expanded use of Acadia's drug Nuplazid to treat psychosis related to Alzheimer's disease. Acadia said it plans to make the drug available to patients by the end of April. He forecast peak U.S. trofinetide sales of $487.2 million by 2035. After the FDA declined to approve the expanded use of Nuplazid, Acadia said it would not pursue that indication for Nuplazid further. Improvement of symptoms was measured according to the assessment scales Rett Syndrome Behaviour Questionnaire and the Clinical Global Impression of Improvement.
☆ U.S. FDA approves Acadia's genetic Rett syndrome drug
  + stars: | 2023-03-11 | by ( ) www.reuters.com   time to read: +3 min
March 10 (Reuters) - The U.S. Food and Drug Administration approved Acadia Pharmaceuticals Inc's (ACAD.O) drug for the treatment of Rett syndrome, a genetic brain disorder, the company said on Friday, making it the first approved drug for the condition. The approval comes months after the FDA declined to approve expanded use of Acadia's drug Nuplazid to treat psychosis related to Alzheimer's disease. Acadia said it plans to make the drug available to patients by the end of April. He forecast peak U.S. trofinetide sales of $487.2 million by 2035. Improvement of symptoms was measured according to the assessment scales Rett Syndrome Behaviour Questionnaire and the Clinical Global Impression of Improvement.
0 next >>
Total: 4